|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Paraneoplastic Autoantibody Evaluation with Recombx®, CSF
Test Code94603
CPT Codes
86255 (x3), 83520 (x8)
Includes
Recombx® Hu Autoantibody Test
Recombx® Yo Autoantibody Test
Recombx® Zic4 Autoantibody Test
Recombx® CV2 Autoantibody Test
Recombx® MaTa Autoantibody Test
Recombx® Ri Autoantibody Test
Recombx® CAR (Anti-Recoverin) Autoantibody Test
Recombx® Amphiphysin Autoantibody Test
NMDA Receptor Antibody Test
CASPR2 Antibody Test
LGI1 Antibody Test
Recombx® Yo Autoantibody Test
Recombx® Zic4 Autoantibody Test
Recombx® CV2 Autoantibody Test
Recombx® MaTa Autoantibody Test
Recombx® Ri Autoantibody Test
Recombx® CAR (Anti-Recoverin) Autoantibody Test
Recombx® Amphiphysin Autoantibody Test
NMDA Receptor Antibody Test
CASPR2 Antibody Test
LGI1 Antibody Test
Preferred Specimen
2 mL CSF collected in a sterile, leak-proof container
Minimum Volume
0.5 mL
Instructions
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay • Immunofluorescence Assay (IFA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Wed, Fri; Report available: 7-10 days
Reference Range
See Laboratory Report
Clinical Significance
Anti-Hu, anti-CV2, anti-Yo, anti-Ri, anti-CAR, anti-Ma, anti-Ta, anti-Zic4, anti-Amphiphysin, anti-NMDA receptor (NR1-subunit), anti-LGI1 and anti-CASPR2 are found in patients with the acute or subacute onset of limbic encephalitis, brainstem encephalitis, focal cortical encephalitis, myelitis, cerebellar degeneration, opsoclonus/ myoclonus, retinopathy, sensory neuropathy, autonomic dysfunction, Stiff Person Syndrome and/or Lambert-Eaton Myasthenic Syndrome. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.
